INTRODUCTION
One of the goals of precision medicine is to use pharmacogenomics to optimize treatment efficacy and minimize adverse drug reactions. Barriers to the implementation of pharmacogenomics-guided therapy include the turnaround time for obtaining a pharmacogenetic (PGx) result 1 and the clinical utility of returning PGx variants. 2 One recommendation for avoiding treatment delays is to implement preemptive PGx testing. 1 Current PGx testing uses array-based genotyping platforme.g., Affymetrix DMET Plus (Drug Metabolizing Enzymes and Transporters array)-screens for a predefined set of PGx variants. 3, 4 Genomic testing platforms such as exome sequencing (ES) or genome sequencing (GS), 5 also called massively parallel sequencing (MPS), have potentially wider utility than the aforementioned genotyping platforms, and this begs the question of whether MPS sequence data could be used for preemptive PGx testing. Part of the larger challenge for the field of medical genomics is to identify all potential uses of sequencing so that the cost of these assays can be amortized across multiple applications, thereby decreasing the effective cost of the test. Prior studies with small sample sizes showed high ES genotype concordance rate with other platforms (99.6% with MiSeq and 98.9% with iPLEX ADME PGx panel) 6 and variable (60-80%) ES coverage of DMET Plus PGx variant positions depending on the capture kit used. 7 An extensive analysis with a larger data set was needed to assess the capability of ES in detecting clinically relevant PGx variants. We set out to assess MPS concordance and coverage of annotated PGx variants compared with a current genotyping platform to determine whether MPS could serve as a genotyping source for preemptive PGx testing.
MATERIALS AND METHODS

Participants
This study was performed at the NIH Clinical Center as part of the ClinSeq project and included 973 participants enrolled between 45 and 65 years of age who were consented for baseline clinical tests, ES and/or GS, return of genetic results, and iterative phenotyping based on an individual's genetic variants. 8, 9 The National Human Genome Research Institute 
Selection of clinically relevant pharmacogenetic variants for comparison
We identified 50 Pharmacogenomics Knowledgebase (Pharm-GKB) level 1A and 1B PGx variants (https://www.pharmgkb.org/) and 154 Clinical Pharmacogenetics Implementation Consortium (CPIC) (http://www.pharmgkb.org/page/cpic) variants from 40 gene-drug pairs with level A evidence (two promoter variants were located at the same genomic position) for a total of 203 PGx variant positions. We evaluated coverage of these 203 PGx variant positions from 973 exomes, 5 genomes, and 5 chip data. Three HLA-B variants (HLA-B*52:01:01, HLA-B*57:01:01, HLA-B*58:01:01) were excluded because they were not amenable to genotyping by the chip, ES, or GS. MPS genotype concordance was determined by comparing five individuals with ES, GS, and DMET Plus genotypes (hereafter referred to as the chip). The chip has been previously shown to have high genotype concordance (91 to 99%) compared with six orthogonal genotyping platforms. 10 We selected CYP2D6 for copy-number variant (CNV) analysis because 1-2% of individuals carry more than two functional copies that may have an ultrarapid metabolizer phenotype that can lead to codeine toxicity.
11
Laboratory methods
See Supplementary Methods online. We next examined the detection rate of high-quality genotypes (GQ ≥50) per individual at 203 positions. We included 973 exomes captured with four kits (Agilent38Mb, Agilent50Mb, TruSeqV1, TruSeqV2). ES, GS, and chip data were grouped as coding and noncoding variants (intergenic, intronic, promoter, or 3ʹ untranslated region). GS and ES detected an average of 101 and 120 genotypes per individual at coding positions, respectively. At noncoding positions, GS and ES detected an average of 55 and 27 genotypes per individual, respectively (Figure 2a,b; ES average based on TruSeqV1 and V2 data). ES coverage was the highest in coding regions and the TruSeqV2 kit had the highest average (122); the chip captured 45 genotypes per individual (Figure 2a) . ES coverage in noncoding regions was low. Among the 71 noncoding positions, TruSeqV1/V2 had the highest average (27) and the Agilent38Mb kit and the chip had the lowest average (14) of genotypes per individual (Figure 2b) . GS coverage was outperformed by the Agilent50Mb and TruSeqV1/V2 kits in coding regions (Figure 2a; Supplementary Table S4 online) . 
RESULTS
Detection
Brief report
Detection of CPIC and PharmGKB pharmacogenetic variants and rare loss-of-function variants in known pharmacogenes
ES identified 36 star (*) allele variants with CPIC recommendations for change in therapy, including individuals homozygous for CYP2C19 *2 (n = 18), TPMT *3B, TPMT *3C (n = 5), 12 SLCO1B1 *5 (n = 21), 13 and individuals heterozygous for DPYD*13 (n = 2) and rs67376798 (n = 6) (Supplementary Table S5 online).
14 Twenty individuals with rare loss-of-function and eight with splice variants were identified in eight known pharmacogenes (Supplementary Table S6 online).
Genotype concordance between exomes, genomes, and genotyping chip
The chip had 1,929 unique variant positions and identified 9,598 genotypes for the five samples tested. 15 For these nine individuals, ES data analysis did not find paired-end reads mapping to CYP2D6-CYP2D7P. Our paired-end reads (89 bp) and inserts (180 bp) are short; therefore, the absence of detecting paired-end reads mapping to CYP2D6-CYP2D7P does not rule out the presence of fusion/hybrid genes.
DISCUSSION
Adoption of PGx-guided therapy has been limited by insufficient data to support clinical utility and cost-effectiveness, knowledge gaps in pharmacogenomics, and the inherent delay engendered by PGx testing. We propose leveraging existing MPS data by extracting PGx variants preemptively based on two premises. The first is that thousands of patients are currently undergoing clinical ES and GS, and these data comprise a valuable resource for pharmacogenomics. The second is that the extraction of PGx variants from ES/GS data is part of a larger effort to maximize the utility of ES/GS testing results. Studies have demonstrated how ES data can be used to extract variants for the secondary screening of susceptibility to cancer, malignant hyperthermia, cardiomyopathy, cardiac dysrhythmias, and aortic dissection. [16] [17] [18] [19] We assessed the capability of MPS for preemptive PGx testing by comparing the coverage of 203 important PGx variants in 973 exomes with that of a widely used PGx chip.
ES and GS had several advantages over chip-based testing. The genome-wide coverage of ES and GS allowed coverage of more PharmGKB class 1A, 1B, and CPIC gene-drug level A variants than the genotyping chip and identified both known and yet to be discovered PGx variants in one test.
CYP2D6 is a good example for exploring the ability of ES to interrogate CNVs. XHMM detected complete and partial CYP2D6 deletions and duplications, but the chip only detects deletions.
Limitations of this study include the fact that 399/973 of the ES sequences were generated with the Agilent38Mb capture kit, which accounted for the majority of the NC in the ES data, thus decreasing the coverage of some variant positions. The use of four capture kits provided us an opportunity to assess variance in capture-kit coverage.
Our results showed that high exome genotype concordance rates and higher coverage with the TruSeq capture kits (using GQ ≥50) are consistent with findings from recent studies evaluating exome capability for pharmacogenomics screening.
6,7 An updated array targeting PharmGKB level 1A and 1B and CPIC level A variants may be a more cost-efficient initial screen than exomes; however, panel testing and enhanced exome capture with additional targets in noncoding regions 20 will require periodic updating of the test platform and repeat testing of subjects for future discoveries. Although our results showed that exomes can be used to extract PGx variants, we are not advocating ordering an exome primarily for pharmacogenomics screening because our analyses did not answer the question of whether there is clinical utility and validity for using MPS for preemptive PGx screening for these variants.
We have demonstrated the utility of MPS data for the detection of single PGx variants and CYP2D6 CNVs. Currently, no tools are available to extract and annotate PGx variants from MPS data. We conclude that tools should be developed to extract PGx variants from existing ES and GS data for research and potential future use.
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